Related Experiment Video

Updated: May 17, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

MEK and RAF inhibitors for BRAF-mutated cancers

Sarah Belden1, Keith T Flaherty

  • 1Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.

Expert Reviews in Molecular Medicine
|October 13, 2012
PubMed

Insights

The mitogen-activated protein kinase (MAPK) pathway is crucial in cancer. Inhibiting key components like RAF and MEK shows promise, especially for BRAF-mutant melanoma, with ongoing research for RAS-mutant cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling Pathways

Background:

  • The mitogen-activated protein kinase (MAPK) pathway, involving RAS-RAF-MEK-ERK signaling, is frequently dysregulated in cancer.
  • Aberrant growth factor receptor activation drives MAPK pathway hyperactivity, contributing to oncogenesis.
  • RAS proteins (KRAS, NRAS, HRAS) are key upstream activators, but direct inhibition is challenging.

Purpose of the Study:

  • To explore the therapeutic potential of targeting the MAPK pathway in various cancers.
  • To investigate the role of RAF and MEK inhibitors in cancers with RAS mutations or growth factor receptor activation.
  • To build upon the success of BRAF and MEK inhibitors in BRAF-mutant melanoma.

Main Methods:

  • Review of existing literature on MAPK pathway signaling in cancer.
  • Analysis of preclinical and clinical data for RAF and MEK inhibitors.
  • Identification of cancer types and subsets dependent on MAPK pathway activation.

Main Results:

  • Activating BRAF mutations identify specific cancer subsets highly dependent on the MAPK pathway.
  • Selective BRAF and MEK inhibitors are effective therapies for BRAF-mutant melanoma.
  • The efficacy of these inhibitors in RAS-mutant or growth factor receptor-driven cancers requires further investigation.

Conclusions:

  • Targeting the MAPK pathway, particularly RAF and MEK, is a validated therapeutic strategy for certain cancers.
  • Further research is needed to optimize the use of MAPK inhibitors in a broader range of malignancies, including those with RAS mutations.

More Related Videos

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...